January 12, 2022 03:45 PM ESTUpdated January 14, 08:59 AM
R&D

#JPM22: 4 top R&D chiefs dis­cuss the key forces re­shap­ing bio­phar­ma

John Carroll

Editor & Founder

On Tues­day I had a chance to sit down with 4 top R&D chiefs of some of the biggest or­ga­ni­za­tions in the in­dus­try. There’s no …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Eikon Ther­a­peu­tics rais­es $351M Se­ries D as lead drug starts Phase 3

Mer­ck says Keytru­da could be up next for IRA price cuts

Leo Phar­ma says its years­long makeover is about to pay off

Gink­go un­cer­tain over the fu­ture of US gov­ern­ment fund­ing, stock drops

Where the mon­ey is: The top 100 ven­ture in­vestors in biotech

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times